<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00029900</url>
  </required_header>
  <id_info>
    <org_study_id>FD-R-2003-01</org_study_id>
    <secondary_id>FD-R-002003-01</secondary_id>
    <nct_id>NCT00029900</nct_id>
  </id_info>
  <brief_title>ADI-PEG in Patients With Metastatic Melanoma</brief_title>
  <official_title>Phase I Testing of ADI-PEG in Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FDA Office of Orphan Products Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      This is a study to determine the safety and toxicity of increasing doses of arginine&#xD;
      deiminase combined to polyethylene glycol (ADI-PEG) in patients with nonresectable metastatic&#xD;
      melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of amino acid degrading enzymes derived from microbial sources has proven to be an&#xD;
      effective means of controlling some forms of cancer auxotrophic for nonessential amino acids.&#xD;
      Recently it has been shown that human melanomas are auxotrophic for arginine. As arginine is&#xD;
      a nonessential amino acid for humans, elimination of it may prove to be an effective method&#xD;
      for controlling cancer. Laboratory studies have provided promising results with the&#xD;
      arginine-degrading enzyme arginine deiminase (ADI) coupled to polyethylene glycol (PEG) to&#xD;
      enhance its circulating half-life.&#xD;
&#xD;
      In this study, patients each receive 3 intramuscular treatments of ADI-SS PEG over a 4-week&#xD;
      period. There are 4 cohorts of patients each receiving a different dose level.&#xD;
      Pharmacokinetics, pharmacodynamics, safety and toxicity, and immunogenicity studies will be&#xD;
      performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date>August 2003</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>15</enrollment>
  <condition>Melanoma</condition>
  <condition>Neoplasm Metastasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADI PEG</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Histologically confirmed metastatic melanoma&#xD;
&#xD;
          -  Nonresectable disease&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Progressive disease following standard chemotherapy, radiotherapy, surgery, or&#xD;
             immunotherapy; and no longer responding to therapy&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
          -  Karnofsky performance status 70 or higher&#xD;
&#xD;
          -  Expected survival of at least 12 weeks&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
          -  Albumin greater than 3.0 g/dL&#xD;
&#xD;
          -  SGOT less than 5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase less than 5 times ULN&#xD;
&#xD;
          -  Ammonia less than 55 microg/dL&#xD;
&#xD;
          -  Glucose greater than 60 mg/dL&#xD;
&#xD;
          -  Amylase less than 1.5 times ULN&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm3&#xD;
&#xD;
          -  Patients must use 2 forms of effective contraception&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Prior therapy within the past 4 weeks&#xD;
&#xD;
          -  Ascites or pleural effusion&#xD;
&#xD;
          -  Significant cardiac disease (i.e., New York Heart Association class III or IV heart&#xD;
             disease)&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Concurrent enrollment in another IND study&#xD;
&#xD;
          -  Serious infection requiring antibiotics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2002</verification_date>
  <study_first_submitted>January 24, 2002</study_first_submitted>
  <study_first_submitted_qc>January 24, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2002</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>Dose-Response Relationship, Drug</keyword>
  <keyword>Polyethylene Glycol</keyword>
  <keyword>Arginine Deiminase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

